20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Stealth BioTherapeutics Corp (NASDAQ:MITO) has submitted an elamipretide marketing application to the FDA for Barth syndrome.
- The submission is based on results from the SPIBA-001 Phase 3 Retrospective Natural History Control Trial, which compared data from the TAZPOWER Phase 2/3 trial's open-label portion to match natural history controls.
- SPIBA-001 met its primary and most secondary endpoints, demonstrating elamipretide-mediated improvements in exercise tolerance, strength, and cardiac function assessments.
- Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities often leading to heart failure and reduced life expectancy, recurrent infections, muscle weakness, and delayed growth.
- Related content: Benzinga's Full FDA Calendar
- Yesterday, the United States Patent and Trademark Office issued patents covering elamipretide for Barth syndrome and Barth syndrome-related cardiomyopathy until February 2034.
- Price Action: MITO stock is up 3.42% at $1.21 during the premarket session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!